NathanD.M., SingerD.E., GodineJ.E., HarringtonC.H., PerluterL.C.Retinopathy in older type II diabetics: Association with glucose control.Diabetes.1986; 35: 797–801.
2.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med.1993; 329: 979–86.
3.
BrownleeM., VlassaraH., CeramiM.Nonenzymatic glycosylation and the pathogenesis of diabetic complications.Ann Intern Med.1993; 101: 527–37.
4.
VlassaraH.Serum advanced glycosylation end products: A new class of uremic toxin?Blood Purif.1994; 12: 54–9.
5.
KleinR., KleinB.E., MossS.E., DavisM.D., DeMetsD.L.The Wisconsin epidemiologic study of diabetic nephropathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.Arch Ophthalmol.1984; 102: 527–32.
6.
FriedlanderM.A., WuY.C., ElgawishA., MonnierV.M.Early and advanced glycosylation end products: Kinetics of formation and clearance in peritoneal dialysis.J Clin Invest.1996; 97: 728–35.
7.
MiyataT., UedaY., YoshidaA., SugiyamaS., IidaY.Clearance of pentosidine, an advanced glycosylation end product, by different modalities of renal replacement therapy.Kidney Int.1997; 51: 880–7.
8.
YamadaK., MiyaharaY., HamaguchiK., NakayamaM., NakaoH., NozakiO.Immunohistochemical study of human advanced glycosylation end-products (AGEs) in chronic renal failure.Clin Nephrol.1994; 42: 354–61.
9.
NakayamaM., KuboH., OgawaA., YamamotoY., KatoN., HayakawaH.Immunohistochemical detection of advanced glycation end products (AGEs) in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int.1997; 51: 182–6.
10.
VlassaraH., FuhH., MakitaZ., KrungkraiS., CeramiA.Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications.Proc Natl Acad Sci U SA.1992; 89: 12043–7.
11.
BrownleeM., CeramiA., VlassaraH.Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.N Engl J Med.1988; 318: 1315–21.
12.
HeimbürgerO., WaniewskiJ., WerynskiA., LindholmB.A quantitative description of solute and fluid transport during peritoneal dialysis.Kidney Int.1992; 41: 1320–32.
HeimbürgerO., WaniewskiJ., WerynskiA., TranæusA., LindholmB.Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity.Kidney Int.1990; 38: 495–506.
BreborowiczA., BalaskasE., OreopoulosG.D., MartisL., SerkesK., OreopoulosD.G.In vitro study of the effect of osmotic solutes on the interactions between cells from the peritoneum and peritoneal cavity.Perit Dial Int.1994; 14: 149–54.
BreborowiczA., RodelaH., KaronJ., MartisL., OreopoulosD.G.In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells.Am J Kidney Dis.1997; 29: 404–9.
19.
HaH., YuM.R., ParkM.S., LeeH.B.High glucose-induced TGF -β1 and fibronectin synthesis by human peritoneal mesothelial cell: Involvement of PKC [Abstract].Perit Dial Int.1998; 18: 111.
20.
DobbieJ.W.Morphology of the peritoneum in CAPD.Blood Purif.1989; 7: 74–85.
21.
DobbieJ.W.Monitoring of peritoneal histopathology in peritoneal dialysis: The role of a biopsy registry.Nephrol Dial Transplant.1989; 18: 319–35.
22.
KilzerP., ChangK., MarvelJ., RowoldE., JaudesP., UllensvangS.Albumin permeation of new vessels is increased in diabetic rats.Diabetes.1985; 34: 333–6.
23.
LeeH.B., ParkM.S., HanD.C.Hwang SD. Stability of peritoneal solute and water transfer.Korean J Nephrol.1991; 10: S7–16.
24.
LeeH.B., ParkM.S., ChungS.H., SoI.N., HanD.C., LeeS.K.Peritoneal membrane performance after 5 years of CAPD. fu: Current Concepts in Peritoneal Dialysis. Kyoto: Elsevier Science Publishers; 1992: 84–8.
25.
SelgasR., BajoM.A., PaivaA., DelPasoG., DiazC., ArgueleraA.Stability of the peritoneal membrane in long-term peritoneal dialysis patients.Adv Ren Re place Ther.1998; 5: 168–78.
26.
KredietR.T.Prevention and treatment of peritoneal dialysis membrane failure.Adv Ren Replace Ther.1998; 5: 212–17.
27.
MonquilM.C., ImholzA.L., StruijkD.G., KredietR.T.Does impaired transcellular water transport contribute to net ultrafiltration failure during CAPD?Perit Dial Int.1995; 15: 42–8.
28.
EbleA.S., ThorpeS.R., BaynesJ.W.Nonenzymatic glycosylation and glucose-dependent cross-linking of protein.J Biol Chem.1983; 258: 9406–12.
29.
FriedlanderM.A., Witko-SarsatV., NguyenA.T., WuY.C., LabrunieM., VergerC.The advanced glycation endproduct pentosidine and monocyte activation in uremia.Clin Nephrol.1996; 45: 379–82.
30.
AteshkadiA., JohnsonC.A., FoundsH.W., ZimmermanS.W.Serum advanced glycosylation end-products in patients on hemodialysis and CAPD.Perit Dial Int.1995; 15: 129–33.
31.
MaihoutA., EhlerdingG., BrunkhorstR.Advanced glycation end-products in the peritoneal fluid and in the peritoneal membrane of continuous ambulatory peritoneal dialysis patients.Nephrol Dial Transplant.1996; 11(Suppl 5): 2–6.
32.
LambE., Cat tellW.R., DawnayA.Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis.Clin Sci.1993; 84: 619–26.
33.
MiyataT., WadaY., CalZ., HorieK., YasudaY., MaedaK.Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end stage renal failure.Kidney Int.1997; 51: 1170–81.
34.
WeissM.F.Pathogenic role of advanced glycation endproducts (AGEs): An overview.Perit Dial Int.1999; 19(Suppl 2): S47–52.
35.
MiyataT., IzuharaY., SakaiH., KurokawaK.Carbonyl stress: Increased carbonyl modification of tissue and cellular proteins in uremia.Perit Dial Int.1999; 19(Suppl 2): S58–61.
36.
Ho-dac-PannekeetM.M., WeissM.F., de WaartD.R., ErhardP., HiralallJ.K., KredietR.T.Analysis of non enzymatic glycosylation in vivo: Impact of different dialysis solutions.Perit Dial Int.1999; 19(Suppl 2): S68–74.
37.
BrownleeM., VlassaraH., CeramiA.Nonenzymatic glycosylation and the pathogenesis of diabetic complications.Ann Intern Med.1984; 101: 527–37.
38.
DobbieJ.W., AndersonJ.D., HindC.Long-term effect of peritoneal dialysis on peritoneal morphology.Perit Dial Int.1994; 14: S16–20.
39.
DobbieJ.W.New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis.Am J Kidney Dis.1990; 15: 97–109.
40.
GotloibL., Bar-SellaP., ShostakA.Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum: Ultrastructural changes of reduplicated peritoneal basement membrane.Perit Dial Bull.1985; 5: 212–15.
41.
Di PaoloN., SacchiG.Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vitro model for the study of diabetic microangiopathy.Perit Dial Int.1989; 9: 41–5.
ParkM.S.Factors increasing severity of peritonitis in long-term peritoneal dialysis patients.Adv Ren Replace Ther.1998; 5: 185–93.
44.
WeissM.F., SaxenaA.K., MonnierV.M.Pharmacological modulation of AGEs: A unique role for redox-active metal ions.Perit Dial Int.1999; 19(Suppl 2) S62–67.
45.
WieslanderA., DeppischR., SvenssonE., ForsbackG.In vitro biocompatibility of a heat sterilized, low toxic and less acidic fluid for peritoneal dialysis.Perit Dial Int.1995; 15: 158–64.
